Data / Research funding / Osteogenesis Imperfecta
Osteogenesis Imperfecta: 30 NIH awards ($32.8M) to 17 organizations
30 NIH awards ($32.8M) in the NIH spending category Osteogenesis Imperfecta, to 17 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
30 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Brittle Bone Disorders Consortium of the Rare Disease Clinical Research Network | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $6,852,525 | September 15, 2014 | August 31, 2030 | LEE, BRENDAN | reporter.nih.gov |
| NIH Osteoporosis and Related Bone Diseases~National Resource Center (NRC) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $4,052,641 | January 15, 2018 | January 14, 2023 | BOWEN, MATT | reporter.nih.gov |
| WNT1 Function in Stem Cells in Osteogenesis Imperfecta and Craniofacial-Skeletal Tissues | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2025 | $2,862,721 | September 10, 2021 | August 31, 2026 | LEE, BRENDAN | reporter.nih.gov |
| Regulation of Skeletal progenitor cells in Osteogenesis Imperfecta | NIH | National Institute of Dental & Craniofacial Research | 2022 to 2025 | $2,636,174 | July 13, 2022 | April 30, 2027 | PARK, DONGSU | reporter.nih.gov |
| TASK ORDER FOR TWO NATIONAL INFORMATION CLEARNINGHOUSES | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $2,222,528 | January 15, 2023 | June 14, 2024 | ROBINSON, NATE | reporter.nih.gov |
| Targeting TGFb In Osteogenesis Imperfecta | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2025 | $1,840,003 | September 7, 2023 | June 30, 2028 | BAE, YANGJIN | reporter.nih.gov |
| Mechanism of growth deficiency in dominant forms of osteogenesis imperfecta | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2024 | $1,335,807 | September 1, 2020 | August 31, 2025 | OTSURU, SATORU | reporter.nih.gov |
| The LRP5 Pathway and Osteoblast Function In Osteogenesis Imperfecta | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2022 | $1,227,998 | September 1, 2018 | June 30, 2024 | JACOBSEN, CHRISTINA MARIE | reporter.nih.gov |
| Investigating pulmonary complications due to abnormal collagen/ER stress in Osteogenesis Imperfecta | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,170,000 | February 15, 2023 | January 31, 2028 | ZIEBA, JENNIFER | reporter.nih.gov |
| Lung developmental defects caused by type I collagen mutations in mouse models of osteogenesis imperfecta | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,155,526 | September 1, 2023 | July 31, 2027 | MORELLO, ROY | reporter.nih.gov |
| EOI:: IMPLEMENTING THE PRESIDENTS DEPARTMENT OF GOVERNMENT EFFICIENCY COST EFFICIENCY INITIATIVE (MARCH 19, 2025):: EOI PARTIAL TERMINATION FOR CONVENIENCE AGREEMENT FOR NIAMS INFORMATION TECHNOLOGY S | NIH | National Heart, Lung, and Blood Institute | 2025 | $1,114,680 | September 25, 2024 | June 30, 2026 | MILLER, CAROL | reporter.nih.gov |
| Development of a long-lasting, bone-targeted gene therapy for osteogenesis imperfecta | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2025 | $667,125 | July 5, 2025 | June 30, 2030 | SHIM, JAE-HYUCK | reporter.nih.gov |
| A molecular pathway that links N-glycosylation to birth defects | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 to 2025 | $663,920 | July 1, 2024 | April 30, 2029 | ROHATGI, RAJAT | reporter.nih.gov |
| Preclinical Testing of Early Life Anti-Myostatin Therapy for Osteogenesis | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2025 | $652,723 | August 14, 2025 | April 30, 2030 | OESTREICH, ARIN KETTLE | reporter.nih.gov |
| Biomarking the Sclerostin Antibody Effects on Osseointegration in an Osteogenesis Imperfecta Model | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2024 | $599,851 | July 1, 2021 | June 30, 2025 | SUNG HSIEH, HSIAO HSIN | reporter.nih.gov |
| Neurobehavioral phenotypes of mouse models of Osteogenesis Imperfecta | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2022 | $426,004 | June 2, 2021 | May 31, 2023 | WARMAN, MATTHEW L | reporter.nih.gov |
| Conditional mouse models with dominant negative Osteogenesis Imperfecta | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2024 | $422,499 | March 1, 2023 | April 30, 2025 | WARMAN, MATTHEW L | reporter.nih.gov |
| Novel bone specific pharmacological treatment for osteogenesis imperfecta | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $419,606 | August 1, 2021 | July 31, 2024 | CARRIERO, ALESSANDRA | reporter.nih.gov |
| A NOTCH2 Mutation Causes Osteogenesis Imperfecta | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2024 | $395,161 | April 1, 2023 | February 28, 2026 | CANALIS, ERNESTO | reporter.nih.gov |
| Precision Gene Editing on Osteogenesis Imperfecta | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 to 2025 | $386,925 | September 1, 2024 | August 31, 2026 | SATO, TADATOSHI | reporter.nih.gov |
| Cellular Therapy for Osteogenesis Imperfecta | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2025 | $386,481 | May 1, 2025 | March 31, 2030 | KALAJZIC, IVO | reporter.nih.gov |
| Preclinical testing of early life anti-myostatin therapy for osteogenesis imperfecta | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 | $217,371 | August 1, 2023 | July 31, 2025 | PHILLIPS, CHARLOTTE L | reporter.nih.gov |
| Super resolution label-free imaging in highly scattering bone | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 | $177,500 | May 1, 2019 | January 31, 2023 | MORTENSEN, LUKE J. | reporter.nih.gov |
| Development of a novel therapy with Apolipoprotein E for osteogenesis imperfecta | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 | $164,851 | September 11, 2020 | August 31, 2022 | OTSURU, SATORU | reporter.nih.gov |
| Maternal Anti-myostatin (GDF8) Therapy to Enhance Offspring Musculoskeletal Health in Mouse Models of Osteogenesis Imperfecta | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 | $164,451 | July 15, 2020 | June 30, 2023 | PHILLIPS, CHARLOTTE L | reporter.nih.gov |
| Engineering 3D biomimetic osteogenesis imperfecta models to dissect mechanisms of N-cadherin mediated osteoblast-endothelial function | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 | $163,392 | September 1, 2020 | July 15, 2022 | ALIMPERTI, STELLA | reporter.nih.gov |
| Osteogenesis imperfecta caused by TMEM38B mutation: a deep investigation of cellular and extracellular consequences to identify new therapeutic targets | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 | $159,594 | September 25, 2024 | August 31, 2025 | CARRIERO, ALESSANDRA | reporter.nih.gov |
| Mechanistic investigation into Frizzled-2 signaling for treatment of Osteogenesis Imperfecta | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 to 2025 | $146,206 | September 1, 2023 | August 31, 2026 | ADEYEYE, MARY IFEOLUWA | reporter.nih.gov |
| Genetic determinants of endoplasmic reticulum stress in OI and its consequences on cellular receptors | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 to 2025 | $95,897 | March 15, 2024 | March 14, 2027 | KOT, ALEXANDER | reporter.nih.gov |
| INVESTIGATING THE CONTRIBUTION OF OSTEOBLAST DIFFERENTIATION IN THE PATHOGENESIS OF OSTEOGENESIS IMPERFECTA TYPE V | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 | $42,574 | December 1, 2024 | November 30, 2027 | BUSSE, EMILY | reporter.nih.gov |
Organizations
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 14 | $7,641,738 | 0 | $0 |
| 2024 | 16 | $4,577,873 | 0 | $0 |
| 2023 | 13 | $7,171,083 | 0 | $0 |
| 2022 | 9 | $6,991,812 | 0 | $0 |
| 2021 | 12 | $6,440,228 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.